INTRODUCTION
The TWEAK-Fn14 cytokine-receptor axis Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), a member of the TNF superfamily, 1 acts on cells via binding to fibroblast growth factor-inducible 14 (Fn14), a 102-aa type I transmembrane protein that was initially discovered as a growth factor-inducible gene product 2, 3 and then subsequently identified as the TWEAK receptor by Wiley et al. 4 TWEAK is initially synthesized as a type II transmembrane protein but it can be cleaved by furin to generate a soluble cytokine. 1, 5 Both the membrane-anchored and soluble TWEAK isoforms can bind to Fn14. 5, 6 TWEAK:Fn14 engagement promotes Fn14 trimerization and TNF receptor-associated factor binding to the Fn14 cytoplasmic tail, 7 which activates a number of intracellular signal transduction cascades (for example, the nuclear factor-κB (NF-κB) pathway). This can result in increased cell proliferation, survival, migration, differentiation or death, depending on the cellular context ( Figure 1 ). [8] [9] [10] In addition, TWEAK is a pro-inflammatory 11, 12 and pro-angiogenic 13, 14 cytokine in vivo. The TWEAK and Fn14 genes are expressed at low levels in most healthy normal tissues but increased expression has been noted after tissue injury [8] [9] [10] and in many solid primary tumor types and tumor metastases. For example, TWEAK is highly expressed in liver, 15 ovarian, 16 colorectal, 14, 17 bladder, 18 esophageal, 19 pancreatic 19 and prostate 20 cancers, as well as a high percentage of prostate cancer metastases. 20 Fn14 overexpression has been detected in over a dozen solid tumor types, 21, 22 including the tumor types mentioned above 3, 16, [18] [19] [20] 23, 24 , as well as brain cancer (see below), 25, 26 breast cancer, [27] [28] [29] [30] lung cancer 31, 32 and melanoma. 33 It has also been reported that Fn14 is highly expressed in the metastatic lesions of breast, 28 colorectal, 21 melanoma, 33 non-small cell lung 34 and prostate 20 cancer patients. Studies using TWEAK-null mice, Fn14-null mice or anti-TWEAKneutralizing monoclonal antibodies (mAbs) have revealed that transient TWEAK/Fn14 signaling after acute tissue injury is critical for efficient wound repair. [8] [9] [10] However, chronic, dysregulated Fn14 activation has been implicated in the pathophysiology of several prominent human diseases, including cancer, cardiovascular disease, rheumatoid arthritis and inflammatory bowel diseases. [8] [9] [10] [35] [36] [37] [38] Accordingly, a number of TWEAK-or Fn14-targeted therapeutic agents are presently in preclinical development 35, 36 and some agents have progressed into earlyphase clinical trials. 22, 39 Glioblastoma Brain cancer is a biologically and clinically diverse group of intracranial tumors, with most primary intrinsic tumors arising from glial cells (usually astrocytes or oligodendrocytes).
Glial cell tumors, collectively referred to as gliomas, represent 80% of all malignant brain and central nervous system tumors, and glioblastoma (GB; World Health Organization grade IV glioma) 42 is the most common and lethal primary malignant brain tumor, with~10 000 new cases in the United States per year. 43, 44 GB tumors are characterized by extensive vascularization, a high mitotic index, cellular pleomorphism, genomic instability and tissue necrosis. 43 Technological advances during the past decade have allowed investigators to interrogate hundreds of GB surgical specimens at the molecular level using genomic, transcriptomic, epigenomic and proteomic analyses. 41, [45] [46] [47] This research has catalogued the most common genetic alterations associated with this cancer type (that is, gene mutations, amplifications and deletions), thereby revealing several constitutively activated receptor tyrosine kinases and intracellular signaling nodes that may be targeted by precision therapeutics. 41, 45, 48 These studies and others have also demonstrated that although GB tumors exhibit significant intra-tumor molecular heterogeneity, [49] [50] [51] [52] [53] they can be classified into four major subtypes-proneural, neural, classical and mesenchymal-by whole-genome sequencing and expression profiling of surgically resected samples. 41, 45, 47, 48, 50, 54 Each GB subtype is defined by a common genomic landscape, transcriptional profile, disease pathophysiology and patient prognosis. 41, 45, 47, 48, 50, 54 The current standard-of-care for patients with GB consists of maximal surgical resection or biopsy followed by high-dose radiation and concomitant oral chemotherapy using the DNAalkylating agent temozolomide (brand name Temodar), 55 which can cross the blood-brain barrier (BBB) because of its small size and lipophilic properties. Despite this multimodal course of treatment, the median overall survival of GB patients is 15 months after diagnosis, 55, 56 with~95% of patients succumbing to this disease within 5 years. 44 Patients whose tumors exhibit epigenetic silencing of the DNA repair enzyme O 6 -methylguanine-DNA methyltransferase experience the best treatment outcomes; [56] [57] [58] however, disease progression occurs in all patients. One of the primary reasons for poor patient prognosis is that glioma cells are highly invasive; consequently, there is extensive tumor cell infiltration into surrounding healthy brain tissue. [59] [60] [61] These invading cells, which can be found centimeters away from the main tumor mass, cannot be removed by surgical resection of the tumor core or safely targeted by adjuvant radiotherapy because of the potential to harm nearby normal neurons and glial cells. Glioma cells residing in tumor margins are also relatively resistant to chemotherapeutics, primarily due to the BBB; 62 hence, these cells frequently transition from an invasive to a proliferative state, which leads to tumor recurrence, brain injury and patient death. Thus, novel therapies that target the invasive rim cells left behind after surgical resection are sorely needed in order to significantly improve the survival of GB patients. This is a challenging problem, as there are several critical barriers to effective delivery of GB therapeutics (see below). These barriers include the following: (i) the BBB; (ii) the electrostatically charged and anisotropic extracellular space found between brain cells, which contains extracellular matrix (ECM) proteins and proteoglycans; and (iii) the glialymphatic system, 63 a paravascular, pseudolymphatic drainage pathway that can act as a sink for small molecule drugs, gene therapy constructs and protein-based therapeutics. 64, 65 Challenges to GB patient therapy The location of GB tumors presents several unique barriers to systemic drug treatment. 64, 65 First, the BBB, consisting of cerebral endothelial cells connected together by tight junctions, a thick basement membrane, and astrocytic end-feet, controls the passage of most molecules and drugs from the blood circulation to the brain. 62, 66 It has been estimated that 498% of smallmolecule drugs and nearly all biologics (for example, therapeutic mAbs) do not cross the BBB. 67 Although this barrier is altered in the hypoxic core region of advanced brain tumors, 68 unresectable, invading tumor cells are consistently found in brain regions exhibiting a relatively intact BBB. [69] [70] [71] As mentioned above, these invading tumor cells are difficult to treat, owing to their close proximity to functioning brain cells, and contribute to tumor recurrence. Second, the anisotropic, electrostatically charged extracellular space found between brain cells, which contains a dense network of ECM components, 72, 73 comprises 10-20% of total brain volume and acts as a 'brain penetration barrier' for both systemic and local drug delivery. 74, 75 It has been suggested that the extracellular space in brain tumors may constitute a larger percentage of the total brain volume compared with the healthy brain extracellular space, with a more complex, tortuous structure and smaller pores. 76 Several strategies have been proposed to transiently disrupt the BBB to improve the delivery of therapeutic agents to GB tumors (for example, intra-arterial mannitol and focused ultrasound), but each of these methods have limitations that must be overcome before widespread clinical use. 62, 64, 77 In consideration of the challenges associated with systemic drug administration, there is great interest in applying local drug delivery strategies for the treatment of malignant gliomas. 64, 65, 78 Gliadel (Arbor Pharmaceuticals, Atlanta, GA, USA) is a Food and Drug Administration-approved, biodegradable, polyanhydridebased polymer wafer containing the alkylating agent carmustine (N,N'-bis- [2-chloroethyl] -N-nitrosurea), a chemotherapeutic that exhibits high hematologic cell toxicity when administered systemically. [78] [79] [80] These wafers, which are~1.5 cm in diameter, are implanted into the surgical resection cavity following tumor excision. Gliadel wafer implantation produces a small but significant improvement in median patient survival time compared with placebo wafers (~2 months). 78, 79, 81 For this form of interstitial chemotherapy, drug delivery is mediated by diffusion; consequently, Gliadel efficacy is likely limited, at least in part, by the inability to achieve therapeutic drug concentrations more than a few millimeters beyond the immediate tumor resection margin. 79, 82 Another local drug delivery technique that has been used for GB patients is convection-enhanced delivery (CED), which is a hydrostatic and osmotic pressure-driven infusion method to generate bulk flow of therapeutic agents through the brain interstitial spaces. 65, 78, 83 Animal studies and human clinical trials have been carried out using CED as a means to deliver various anti-cancer agents including conventional chemotherapeutics, nanoparticles (NPs), mAbs and targeted toxins to malignant glioma cells. 84 Several limitations to the success of this approach were noted in the early GB CED trials; for example, catheter placement can greatly effect drug delivery [85] [86] [87] [88] and there is a certain degree of drug backflow along the catheter. 78, 89 In addition, even with CED, there is poor drug penetration to the infiltrative glioma cells residing in the invasive rim region (the brain area at risk for tumor recurrence). 88 Accordingly, efforts are underway to optimize the CED approach, including the use of real-time imaging techniques to assess the best catheter positioning and infusion parmeters for effective drug distribution. [90] [91] [92] [93] In summary, for both systemic and local drug delivery methods, the limited penetration of therapeutic agents into tumor cell-infiltrated normal brain tissue remains a key hurdle to increasing the survival of GB patients.
THE TWEAK/FN14 AXIS AND GB
Fn14 gene expression is upregulated in advanced brain cancers and, in particular, in GB tumors exhibiting the mesenchymal molecular subtype The first study reporting that Fn14 gene expression was elevated in GB samples compared with normal brain tissue was published by Tran et al. in 2003. 26 Fn14 mRNA levels were analyzed by real-time quantitative PCR in 3 normal brain samples, 1 oligodendroglioma, 2 pilocytic astrocytomas, 2 low-grade astrocytomas, 4 anaplastic astrocytomas and 16 GBs. The highest expression of Fn14 mRNA was observed in the GB specimens, with 70% of the samples showing fivefold induction over normal brain tissue. Subsequent gene expression profiling experiments using larger sample numbers have confirmed Fn14 mRNA levels are low in normal brain and increase with glioma grade. 25, 94, 95 In addition, it has been reported that Fn14 mRNA expression levels in GB tumors inversely correlate with patient survival. 25 Finally, Fn14 is one of the 37 genes upregulated in the poor prognosis group of a 58-gene signature that is a strong prognostic predictor for patients diagnosed with oligodendroglial or astrocytic tumors, including GB. 96 Elevated Fn14 expression in the GB tumor core has also been observed at the protein level using immunohistochemistry (IHC). 25, 26, 97 In one report, Fn14 expression was examined using a brain tumor tissue microarray and an Fn14-specific mAb, and the stain intensity was scored as negative, weak, moderate or strong. 25 All 9 of the non-neoplastic brain specimens had no staining or weak staining; in contrast, only 4 of the 27 GB specimens were scored negative or weak, whereas the other 23 specimens exhibited moderate or strong staining.
We recently interrogated The Cancer Genome Atlas GB tumor data set to examine Fn14 mRNA expression levels in 195 tumors representing the 4 different GB molecular subtypes that were mentioned above. This analysis revealed that Fn14 gene expression is most frequently upregulated in mesenchymal subtype tumors ( Figure 2 ). Mesenchymal subtype tumors frequently exhibit constitutive NF-κB 98 and STAT3 99 activation; thus, this finding is consistent with studies indicating that Fn14 is an NF-κB-and STAT3/5-regulated gene (Tran, unpublished data). 25, 100 Tumors with the mesenchymal gene expression signature are highly aggressive, invasive tumors that primarily arise de novo, and patients harboring these tumors have the poorest prognosis. 41, 45, 47, 48, 50, 54 Interestingly, some proneural subtype GB tumors, on recurrence, tend to shift toward the mesenchymal subtype, and Phillips et al. 54 have reported that Fn14 mRNA expression is significantly upregulated (~2.4-fold increase) in those recurrent tumors where this phenotypic shift is detected.
The finding that Fn14 is frequently overexpressed in mesenchymal subtype tumors has several clinical implications. First, Halliday et al. 101 recently reported that when mice bearing highgrade gliomas resembling the proneural GB subtype were exposed to ionizing radiation, there was a rapid change in the global gene expression pattern and these changes were indicative of a proneural to mesenchymal subtype phenotypic transition. This implies that Fn14 levels may increase following brain irradiation, which could in theory sensitize radioresistant GB cells to Fn14-targeted therapeutics (see below). Second, Sullivan et al. 102 reported in 2014 that GB patients contain circulating tumor cells, and that these cells express mesenchymal subtype classifier genes and have an invasive phenotype. Accordingly, if these circulating tumor cells express Fn14, one could potentially 179,180 Z-scores were computed by cbioportal.org relative to the expression distribution of each gene in tumors that are diploid for this gene. Patients used in this analysis were limited to the provisional The Cancer Genome Atlas (TCGA) data set. 46 The provisional data set using the Affymetrix U113 microarray platform is the only GB data set with annotation for classical, mesenchymal, neural and proneural expression clusters on cbioportal.org. Patient/ sample sets for each expression cluster were plotted as box and whisker plots. Classical n = 54, mesenchymal n = 56, neural n = 29 and proneural n = 56. Whiskers of the plot map the maximum and minimum Z-score for each expression cluster. Bar in box represents the mean value for the Fn14 Z-score of each group. Top and bottoms of the box represent the 25th and 75th percentile, respectively, of the Fn14 Z-score values for each group. (b) Table showing P-values for significance of mean across GB subtypes for Fn14 expression. Each of the mean expression values are significantly different from one another (P o0.05) as determined using unpaired Student's t-test (two-tailed).
use Fn14 mAbs as an affinity reagent as part of an immunoselection protocol to detect and capture this cell population (that is, liquid biopsy). The GB circulating tumor cells could then be subjected to genomic/transcriptomic analyses to guide patient therapy decisions.
Glioma cells that are migrating on ECM in vitro or invading into brain tissue in vivo express relatively high levels of Fn14 in comparison with stationary cells Mariani et al. 103 reported that plating glioma cell lines on a glioma cell-derived ECM instead of an untreated or bovine serum albumin-treated plastic surface leads to an accelerated migratory rate, and cDNA microarray analysis identified Fn14 as one of the genes that was most significantly upregulated in migrationactivated cells. Elevated Fn14 gene expression in migrating glioma cells was subsequently confirmed using northern and western blot analyses. 26 To test whether Fn14 was also overexpressed in glioma cells invading in vivo, Tran et al. 25 collected GB tumor core and invasive rim cells from three surgical specimens by laser capture microdissection, isolated RNA and examined Fn14 transcript levels by real-time quantitative PCR. They found a four-to sixfold induction of Fn14 transcript in the cells located at the rim compared with matched core cells. Two IHC studies have confirmed high Fn14 gene expression in invasive rim cells. 25, 104 In the most extensive study, Fortin et al. 104 prepared a glioma invasion tissue microarray containing representative punches of tumor core, edge and invasive rim from 44 GB specimens and Fn14 immunostaining intensity was scored as negative, weak, moderate or strong. They found that 94.4%, 88.4% and 100% of the core, edge and rim samples, respectively, had either moderate or strong Fn14 expression. A representative example of IHC staining of normal brain tissue and the invasive rim region of an Fn14-positive GB surgical specimen is shown in Figure 3 . The molecular basis for elevated Fn14 gene expression in migrating/ invading glioma cells compared with stationary cells is not known; however, as mentioned above, Fn14 is an NF-κB-inducible gene, 25, 100 and Dhruv et al. 105 have reported that increased NF-κB activity is associated with glioma cell migration in vitro and invasion in vivo.
TWEAK treatment of Fn14-positive glioma cells stimulates migration, invasion and resistance to chemotherapeutic agents in vitro Although TWEAK is the only known ligand for Fn14, there have been only three reports comparing TWEAK gene expression in normal brain versus brain tumors. Tran et al. 26 assayed TWEAK mRNA expression levels in normal brain versus GB tissue using real-time quantitative PCR and found that TWEAK mRNA was downregulated in 9/10 GB samples. In a second study by this same group, TWEAK gene expression levels were mined in an Affymetrix gene expression profile data set consisting of 24 non-neoplastic brain samples and 160 surgical samples representing different glioma tumor grades, including 82 GB specimens. TWEAK mRNA expression was detected but expression levels did not vary across the sample set. 25 In a recent report, TWEAK protein expression was detected in low-and high-grade glioma specimens by IHC. 97 Taken together, these studies indicate that the TWEAK cytokine is most likely present in the GB tissue microenvironment and for this reason it is of interest to determine the effect of TWEAK:Fn14 engagement on glioma cell biology.
It has been shown that TWEAK treatment of various Fn14-positive glioma cell lines (for example, SF767, U118, T98G, U87 and A172) stimulates cell migration in both a microliter-scale radial assay using laminin-coated glass slides 26, 106, 107 and in a modified Boyden chamber assay with TWEAK added to the lower well culture medium. 108 Important molecular mediators of this cellular response have been identified, including TNF receptorassociated factor-2, 107 the Src family kinase member Lyn, 108 the guanine nucleotide exchange factors SGEF, Ect2 and Trio, and the Rho GTPases Rac1, Cdc42 and RhoG. 106, 107 Several of these signaling proteins, including Lyn 108 and SGEF, 107 are overexpressed in GB tumors. Recently, Cherry et al. 109 reported that TWEAK also stimulates glioma cell invasion using a threedimensional type 1 collagen matrix assay. They also found that TWEAK:Fn14 engagement increased matrix metalloprotease-9 gene expression, consistent with a previous report using T98G glioma cells, 110 and that TWEAK pro-invasive activity was reduced in the presence of the pan-matrix metalloprotease inhibitor GM6001.
Finally, two studies have demonstrated that activation of the TWEAK/Fn14 axis can promote glioma cell survival following exposure to the pro-apoptotic TNF superfamily member TNF-related apoptosis-inducing ligand or the chemotherapeutic agents camptothecin (a DNA topoisomerase 1 inhibitor) and temozolomide (mentioned above).
104,111 TWEAK-triggered cell survival is mediated, at least in part, by activation of the NF-κB and Akt2 signaling pathways, and the enhanced expression of the anti-apoptotic proteins Bcl-X L and Bcl-W. 104, 111 Interestingly, IHC analysis of 44 GB specimens revealed a positive correlation between Fn14 and Akt2 expression levels. 104 A summary of the molecular pathways currently implicated in TWEAK regulation of glioma cell migration, invasion and survival is shown in Figure 4 . Many of these same pathways may be stimulated by TWEAKindependent Fn14 activation as well (see below). 106 reported that adenovirus-mediated overexpression of full-length, wild-type Fn14, but not an Fn14 cytoplasmic tail deletion mutant that is unable to bind TNF receptor-associated factors and activate intracellular signaling cascades, increases U118 and T98G glioma cell invasion in an ex vivo rat brain slice invasion assay. These authors also assessed the ability of Fn14 to promote mouse astrocyte migration in vivo using the replication-competent avian sarcoma leukosis virus long-terminal repeat with splice acceptor/tumor virus A gene delivery system. 112 For these experiments, chicken DF-1 cells infected with an replication-competent avian sarcoma-Fn14 construct were delivered intracranially into transgenic mice engineered to express tumor virus A, the avian cell surface receptor for the replication-competent avian sarcoma virus, under control of the astrocyte-specific glial fibrilic acid protein promoter. They found that forced Fn14 expression induced mouse astrocyte migration in the brain.
High Fn14 expression levels in glioma cells
One issue with the Fn14 overexpression studies described above is the possibility that the amount of Fn14 produced in cells engineered to overexpress this receptor may greatly exceed the Fn14 levels found in glioma cells in vivo, which could trigger nonphysiological Fn14 functions. Accordingly, it is important to note that Fn14 siRNA-mediated downregulation of endogenously expressed Fn14 in glioma cells reduces invasive capacity in the rat brain slice invasion assay. 25 Taken together, these Fn14 overexpression/depletion studies support the possibility that elevated Fn14 gene expression in GB tumors may have important biological consequences (for example, increase glioma cell invasiveness) even in the absence of the Fn14 ligand TWEAK. Indirect evidence supporting the concept of TWEAK-independent Fn14 signaling was summarized in two earlier review articles; 8, 113 however, the strongest experimental evidence for this signaling mechanism was published in 2013. 114 In this report, Brown et al. 114 showed that the transient overexpression of an Fn14 mutant that is unable to bind TWEAK can activate the NF-κB pathway. The most likely explanation for this finding is that Fn14 overexpression in cells triggers receptor self-association ('multimerization'), which leads to TNF receptorassociated factor binding and downstream signaling. If Fn14 expression levels alone can regulate Fn14 signaling output in vivo, then this would have obvious clinical implications. Specifically, if TWEAK-independent Fn14 signaling is the main driver of GB pathophysiology, then TWEAK/Fn14 axis-directed therapeutic agents that act by blocking TWEAK binding to Fn14-positive cells may not be ideal for GB patient use. Several agents of this type have been described in the literature, including TWEAKneutralizing mAbs, 22, 115 Fn14-directed mAbs 116, 117 and the Fn14-binding small molecule L524-0366. 118 Therapeutic strategies that leverage Fn14 overexpression in GB tumors as a way to deliver cytotoxins or chemotherapy drugs to glioma cells while sparing healthy neurons and glial cells Comprehensive overviews of the various TWEAK/Fn14 axistargeted therapeutic agents in development were published recently. 35, 36 Here we will focus on two therapeutic strategies that use Fn14 as a cell surface portal for the delivery of pro-apoptotic proteins or chemotherapeutic agents into cancer cells; in the context of GB, the ultimate goal is to kill the Fn14-positive invasive rim cells that cannot be safely removed by surgery. The proposal that Fn14 may be an excellent drug delivery portal is supported by recent work by Gurunathan et al. 119 demonstrating that the steady-state Fn14 expression level in most cells reflects a dynamic process, whereby Fn14 is constitutively synthesized, trafficked to the plasma membrane, internalized and degraded. In particular, constitutive Fn14 expression and endocytosis may result in more efficient and sustained delivery of Fn14-targeted therapeutics into the intracellular compartment. Strategy 1: Fn14-targeted, fully humanized recombinant fusion proteins with cytotoxic activity Targeted toxins are a class of cancer therapeutics that bind to cell surface proteins (usually plasma membrane-anchored receptors), become internalized via receptor-mediated endocytosis and release a cytotoxic payload. 120 The cell surface proteins targeted by these therapeutics are expressed at higher levels in tumors when compared with the corresponding normal tissue type; consequently, they are often described as tumor-associated antigens. Targeted toxins are typically recombinant fusion proteins consisting of a targeting moiety (for example, a receptor ligand or receptor-specific mAb fragment; mAb-based targeted toxins are generally referred to as 'immunotoxins') and a cellkilling moiety (for example, Pseudomonas aeruginosa exotoxin A or Cornynebacterium diphtheriae toxin). Targeted toxins that use modified bacterial, fungal or plant toxins as their cell-killing moiety all act on eukaryotic cells via inhibition of protein synthesis. A number of targeted toxins have been developed for potential use in GB patients and several have advanced to human clinical trials. 121, 122 Some of the 'GB tumor-specific' cell surface proteins targeted by these constructs include podoplanin, 123 glycoprotein NMB, 124 and IL-13Rα2. 85, 134, 135 Bispecific constructs targeting two different GB cell surface proteins have also been described. 121, 122, 136 Only one targeted toxin, IL13-PE38QQR (Cintredekin Besudotox), a fusion protein composed of human IL-13 and a truncated, mutated version of P. aeruginosa exotoxin A, has been evaluated in a large phase III randomized GB clinical trial (the PRECISE trial). 137 In this trial, IL13-PE38QQR was administered via CED and efficacy was compared with Gliadel wafer implantation. Although the targeted toxin was well tolerated, there was no statistically significant improvement in survival compared with the wafer. Several possible reasons for this outcome have been proposed, including the likelihood that perhaps o 50% of the patients enrolled in the trial may have actually harbored IL-13Rα2-positive tumors, 138 suboptimal catheter placement [85] [86] [87] [88] and poor drug distribution. 88 As Fn14 is frequently overexpressed in a wide variety of human primary cancers and metastases (discussed above), it is a cell surface target for precision therapeutic development for agents such as targeted toxins. In the context of GB therapy, Fn14 is perhaps a more appealing target than many of the other cell surface receptors mentioned above, because (i) there is minimal expression in normal brain and most GB tumors are Fn14-positive (~70-85%), (ii) Fn14 overexpression has been confirmed in both the stationary and invasive glioma cell populations and (iii) Fn14 undergoes constitutive receptor internalization, which could facilitate toxin delivery (discussed above). In addition, in the context of choosing a therapeutic strategy best suited for killing Fn14-positive invading glioma cells, it is of interest to note that there is evidence that glioma cell migration/invasion and proliferation are mutually exclusive processes, that is, migrating cells are not proliferating and vice versa (the 'Go or Grow' hypothesis). 105, 139, 140 Thus, Fn14-targeted toxins may be particularly useful for eradication of invasive glioma cells, because targeted toxins, unlike traditional chemotherapeutics or mAb-drug conjugates, can effectively kill quiescent, non-dividing cells. 120 Rosenblum and colleagues 30, 33, 141, 142 have developed several different Fn14-targeted toxins for cancer therapy. The first generation constructs consisted of either the anti-Fn14 mAb ITEM4 (IT4) or a humanized IT4 scFv fragment as the targeting moiety and the plant toxin gelonin as the therapeutic payload. These agents are internalized by Fn14-positive cancer cells, have cytotoxic activity when assayed on a large panel of cancer cell lines in vitro and inhibit xenograft tumor growth when delivered intravenously into immunodeficient mice. 33, 141, 142 The most recently described Fn14-targeted toxins use either human TWEAK or a humanized IT4 scFv fragment as the targeting moiety and the human pro-apoptotic serine protease granzyme B (GrB) as the cell-killing component. 30 These two fusion proteins, unlike all of the targeted toxins employed in the GB clinical trials described to date, are completely human constructs; accordingly, they are not likely to elicit immune responses in patients (which would prevent retreatment). 120 Both GrB-TWEAK and GrB-Fc-IT4 have been shown to display potent cytotoxic activity on Fn14-positive cancer cells and can inhibit the growth of established xenograft tumors in mice. 30 In regard to GB cells, GrB-TWEAK has been shown to promote A172 and U87 cell death in vitro, 30 but GrB-Fc-IT4 has not been tested and in vivo studies have not yet been conducted. As the therapeutic goal is to eradicate the invading glioma cells, GB patient-derived xenograft models are best suited for the in vivo efficacy experiments since patient-derived xenograft tumors generally demonstrate invasive intracranial growth in immunodeficient mice. 143, 144 In addition, for these patient-derived xenograft experiments, it would be desirable to compare two delivery strategies: (i) local administration via new generation CED technology 84, 145 and (ii) systemic administration in conjunction with one of the new approaches under development for localized BBB disruption, such as magnetic resonance-guided focused ultrasound. 77, 146, 147 Strategy 2: Fn14-targeted, brain-penetrating therapeutic NPs Nanotechnology and, in particular, the use of engineered nanocarriers to deliver imaging agents, cytotoxic drugs, RNA-based therapeutics or gene vectors to solid tumors, has the potential to revolutionize cancer diagnosis and therapy. [148] [149] [150] [151] [152] Many different nanoparticulate drug delivery systems have been developed for cancer therapy, including liposomes, polymeric NPs, micelles, dendrimers and polymer-drug conjugates. 148, 150, 153, 154 In general, NP-based chemotherapeutic drug delivery has several advantages over conventional drug administration, including (i) preferential tumor accumulation, which is largely mediated by unique structural alterations in the tumor capillary and lymphatic vascular networks, resulting in a phenomenon known as the enhanced permeability and retention effect, 149, [155] [156] [157] and (ii) sustained and, in some cases, controllable drug release at the tumor site. 148, 149, 154, 158 These properties and others allow systemically administered nanotherapeutics to achieve higher intratumoral drug concentrations than their free drug counterparts, while simultaneously minimizing off-target toxicity in normal tissues, which can translate into improved therapeutic efficacy. One strategy that has been employed by numerous groups in order to further increase tumor cell-specific cytotoxicity in vivo is to decorate the surface of therapeutic nanocarriers with peptides, polypeptide ligands or mAbs recognizing molecules overexpressed on the cancer cell plasma membrane. 157, 159, 160 This approach is frequently referred to as 'active tumor targeting', to distinguish it from the 'passive tumor-targeting' mechanism that occurs via the enhanced permeability and retention effect. 157 Several nanomedicines for non-central nervous system cancers have been approved by the Food and Drug Administration for clinical use, including Doxil (Janssen Biotech Inc., Horsham, PA, USA), a polyethylene glycol (PEG)-modified liposomal formulation of the anthracycline doxorubicin, and Abraxane (Celgene Corporation, Summit, NJ, USA), an albumin-bound NP formulation of the mitotic inhibitor paclitaxel. [149] [150] [151] [152] 154, 158 These formulations are less toxic than their free drug counterparts but only modestly improve patient overall survival, 149, 151 most likely owing to poor penetration through tumor tissue. 64, 161 Indeed, it has been reported that the penetration depth of intravenously The TWEAK/Fn14 axis and glioblastomaadministered Doxil in lung cancer xenograft tissue is only 8-16 μm (1-2 cell layers) beyond the tumor capillary endothelium. 162 Numerous research groups are developing nanotechnologybased biomaterials that can be used for improved imaging and treatment of advanced brain cancers, including GB. [163] [164] [165] In regard to the design of therapeutic, biodegradable nanocarriers for GB patient use, the issue of poor nanomedicine tissue penetration discussed above is of particular concern, as perhaps the best strategy is to deliver the therapeutic particles into the invasive rim at the time of surgery in order to potentially reach and kill the unresected glioma cells embedded within the normal brain parenchyma (Figure 5a ). As mentioned above, CED can 'infuse' therapeutic agents, including NPs, 93, 166, 167 into brain tissue but there is still limited drug distribution due in part to the brain penetration barrier; accordingly, several approaches have been pursued to develop nanocarriers with enhanced brain-penetrating capacity. These approaches include NP surface alterations such as (i) high-density PEGylation to minimize nonspecific binding to brain ECM, [168] [169] [170] and (ii) covalent conjugation of the tissue penetration peptide iRGD. [171] [172] [173] In addition, Zhou et al. 167 reported that relatively small (~70 nm) NPs exhibit enhanced ability to distribute in the brain following CED if they are stored in trehalose to reduce particle aggregation. There is also a significant amount of research underway evaluating whether nanomedicines engineered for 'active tumor targeting' may be the best formulations for GB patient therapy. Surface-modified NPs have been designed to recognize many of the same 'GB tumor-specific' cell surface proteins describe above for targeted toxin therapy, including transferrin receptor, 174, 175 EGFR, 147 EGFRvIII, 176 IL-13Rα 2 177 and Fn14 (see below). Schneider et al. 170 reported the successful engineering of polystyrene NPs with both brain-penetrating ability and an active tumor-targeting function. In this study, a dense low-molecularweight PEG surface coating was employed in order to increase NP penetration into brain tissue and the NPs were targeted to Fn14-positive glioma cells by attaching the Fn14 mAb IT4 to the PEG chains. These Fn14-targeted, brain-penetrating NPs were able to (i) selectively bind to recombinant Fn14 but not brain ECM proteins in surface plasmon resonance (BiaCore) assays, (ii) exhibit increased association with Fn14-positive cells in comparison with Fn14-negative cells and (iii) rapidly diffuse within brain tissue, even though the PEGylated surface was decorated with mAb molecules. In addition, when administered intracranially, the Fn14-targeted, penetrating NPs showed improved tumor cell co-localization in mice bearing human GB xenografts compared with non-targeted, penetrating NPs. It is anticipated that NP formulations of this type might prove more successful that 'conventional' NPs in delivering chemotherapy drugs to the invading glioma cell population while sparing normal healthy brain cells (Figure 5b ). Additional experimentation is required to determine whether the knowledge gained in this initial proof-ofconcept study can be translated to the development of Fn14-targeted, drug-loaded, biodegradable penetrating NPs that can be tested for therapeutic efficacy in invasive patient-derived xenograft and transgenic rodent models of human GB.
CONCLUSIONS
GB is a lethal disease, in large part due to the highly invasive nature of malignant glioma cells, which limits complete surgical removal and dosing of adjuvant therapies owing to the involvement of functioning brain tissue. The proliferation of these cells within the normal brain parenchyma is the basis for tumor recurrence. Tran et al. 26 reported for the first time that the TWEAK receptor Fn14 was highly expressed in GB tissue specimens in comparison with non-neoplastic brain tissue. Since that time, Figure 5 . Adjuvant therapy for GB patients using engineered nanoparticles. (a) Magnetic resonance images obtained from a female 59-yearold GB patient before and after surgical resection are shown. Therapeutic nanoparticles delivered into the invasive rim region at the time of surgery using advanced CED technology could potentially reach the invasive glioma cells outside the immediate resection margin and deliver their cytotoxic payload. (b) Conventional, drug-loaded NPs without a specialized surface coating penetrate poorly through brain extracellular space after CED (normal brain cells indicated with white circles containing black lines; catheter is indicated using dark black V) and Fn14 targeting is restricted to those glioma cells close to the catheter entry point (white circles; Fn14 molecules indicated with rectangles). In contrast, NPs engineered for enhanced brain-penetrating capacity move deeper into the adjacent brain parenchyma and surface decoration with an Fn14 targeting moiety may increase NP binding to the invasive glioma cells.
numerous reports have confirmed and extended these results; 25, [94] [95] [96] [97] in addition, studies have revealed that Fn14 is overexpressed in invasive glioma cells in vivo 25, 104 (Figure 3) , and that manipulating Fn14 expression levels in glioma cells can have an impact on invasion capacity. 25, 106 Fn14 gene mutations have not yet been identified in GB tissue (COSMIC v72); therefore, Fn14 overexpression, which likely leads to constitutive Fn14 signaling, 114 may be the primary Fn14 alteration in this cancer type. Taken together, these studies have identified Fn14 as a promising potential cell surface target for GB therapeutics. The list of possible strategies that could be considered for the development of effective Fn14-targeted therapeutic agents for GB patients is somewhat limited, because Fn14 is not a protein kinase and Fn14-specific mAbs frequently exhibit agonist activity, 35, 116, 117 which could potentially promote glioma cell invasive activity. Here we have described two distinct therapeutic strategies in preclinical development that are designed to exploit glioma cell surface-specific Fn14 overexpression in order to deliver either humanized cytotoxins 30 or chemotherapeutic drug-loaded NPs 170 to malignant, invading glioma cells, while sparing healthy neurons and glial cells. Additional studies are necessary to elucidate whether these therapeutic strategies can be advanced beyond the preclinical stage and ultimately make a significant impact on GB patient survival.
